Drugs / SNV4818
last change Feb 2025 re-read 2 minutes ago

SNV4818

Developed for
cancer
Investigated by
Pikavation Therapeutics, Inc.

Trials 1 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06736704 Feb 2025 → Apr 2027 expected cancer Pikavation Therapeutics, Inc. Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SNV4818 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06736704
Route Oral “taken orally” NCT06736704